Eligibility check
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Step 1 of 5
Where are you located?
We confirm your state so we only show studies you can actually reach.
Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.